

Efficacy and safety of dupilumab in adults with moderate to severely atopic dermatitis inadequately controlled by topical treatments: a randomised, double-blind, placebo-controlled, dose-ranging phase 2b trial

Lancet, The

387, 40-52

DOI: [10.1016/s0140-6736\(15\)00388-8](https://doi.org/10.1016/s0140-6736(15)00388-8)

Citation Report

#	ARTICLE	IF	CITATIONS
2	Molecular Mechanisms of Cutaneous Inflammatory Disorder: Atopic Dermatitis. International Journal of Molecular Sciences, 2016, 17, 1234.	1.8	90
3	Lipid mediators as regulators of human ILC2 function in allergic diseases. Immunology Letters, 2016, 179, 36-42.	1.1	42
4	The path to personalized medicine in asthma. Expert Review of Respiratory Medicine, 2016, 10, 957-965.	1.0	10
5	Immunologic Targets in Atopic Dermatitis and Emerging Therapies: An Update. American Journal of Clinical Dermatology, 2016, 17, 425-443.	3.3	37
6	Multifactorial skin barrier deficiency and atopic dermatitis: Essential topics to prevent the atopic march. Journal of Allergy and Clinical Immunology, 2016, 138, 350-358.e1.	1.5	187
7	IL-13 is a therapeutic target in radiation lung injury. Scientific Reports, 2016, 6, 39714.	1.6	62
8	Advances in atopic dermatitis in 2015. Journal of Allergy and Clinical Immunology, 2016, 138, 1548-1555.	1.5	54
9	Dermatitis atÃ³pica. EMC - DermatologÃa, 2016, 50, 1-22.	0.1	2
10	Targeting the T Helper 2 Inflammatory Axis in Atopic Dermatitis. International Archives of Allergy and Immunology, 2016, 171, 71-80.	0.9	35
11	Dupilumab efficacy and safety in adults with uncontrolled persistent asthma despite use of medium-to-high-dose inhaled corticosteroids plus a long-acting Î²2 agonist: a randomised double-blind placebo-controlled pivotal phase 2b dose-ranging trial. Lancet, The, 2016, 388, 31-44.	6.3	760
12	Dupilumab: a potential new treatment for severe asthma. Lancet, The, 2016, 388, 3-4.	6.3	17
13	New insights into basophil heterogeneity. Seminars in Immunopathology, 2016, 38, 549-561.	2.8	28
14	Itch Management: Treatments under Development. Current Problems in Dermatology, 2016, 50, 71-76.	0.8	5
15	Two Phase 3 Trials of Dupilumab versus Placebo in Atopic Dermatitis. New England Journal of Medicine, 2016, 375, 2335-2348.	13.9	1,467
16	Lipid-specific T cells and the skin. British Journal of Dermatology, 2016, 175, 19-25.	1.4	5
17	Early-onset pediatric atopic dermatitis is TH2 but also TH17 polarized in skin. Journal of Allergy and Clinical Immunology, 2016, 138, 1639-1651.	1.5	309
18	Cellular and molecular immunologic mechanisms in patients with atopic dermatitis. Journal of Allergy and Clinical Immunology, 2016, 138, 336-349.	1.5	465
19	The immunology of asthma. Annals of Allergy, Asthma and Immunology, 2016, 117, 108-114.	0.5	62

#	ARTICLE	IF	CITATIONS
20	Itch in Atopic Dermatitis Management. <i>Current Problems in Dermatology</i> , 2016, 50, 86-93.	0.8	11
21	Topical tofacitinib for atopic dermatitis: a phase III a randomized trial. <i>British Journal of Dermatology</i> , 2016, 175, 902-911.	1.4	356
22	Anti-inflammatory therapies in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2016, 71, 1666-1675.	2.7	33
23	Exploratory Population PK Analysis of Dupilumab, a Fully Human Monoclonal Antibody Against IL-4R α , in Atopic Dermatitis Patients and Normal Volunteers. <i>CPT: Pharmacometrics and Systems Pharmacology</i> , 2016, 5, 617-624.	1.3	57
24	Current complications and treatment of aspirin-exacerbated respiratory disease. <i>Expert Review of Respiratory Medicine</i> , 2016, 10, 1305-1316.	1.0	9
25	Stratum Corneum Tape Stripping: Monitoring of Inflammatory Mediators in Atopic Dermatitis Patients Using Topical Therapy. <i>International Archives of Allergy and Immunology</i> , 2016, 170, 187-193.	0.9	75
27	The "omics"™ revolution: redefining the understanding and treatment of allergic skin diseases. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 469-476.	1.1	36
28	Emerging therapeutics for ocular surface disease. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2016, 16, 477-486.	1.1	12
29	Dupilumab therapy provides clinically meaningful improvement in patient-reported outcomes (PROs): A phase IIb, randomized, placebo-controlled, clinical trial in adult patients with moderate to severe atopic dermatitis (AD). <i>Journal of the American Academy of Dermatology</i> , 2016, 75, 506-515.	0.6	132
30	Endotypes of allergic diseases and asthma: An important step in building blocks for the future of precision medicine. <i>Allergology International</i> , 2016, 65, 243-252.	1.4	151
34	Panimmunoglobulin and IgE-selective extracorporeal immunoadsorption in patients with severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 137, 1882-1884.e6.	1.5	25
35	Atopic eczema. <i>Clinical Medicine</i> , 2016, 16, 66-69.	0.8	26
36	Patient burden of moderate to severe atopic dermatitis (AD): Insights from a phase 2b clinical trial of dupilumab in adults. <i>Journal of the American Academy of Dermatology</i> , 2016, 74, 491-498.	0.6	251
37	Emerging concepts: mast cell involvement in allergic diseases. <i>Translational Research</i> , 2016, 174, 98-121.	2.2	90
38	A mild topical steroid leads to progressive anti-inflammatory effects in the skin of patients with moderate-to-severe atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2016, 138, 169-178.	1.5	62
39	Clinical Trial of Human Umbilical Cord Blood-Derived Stem Cells for the Treatment of Moderate-to-Severe Atopic Dermatitis: Phase I/IIa Studies. <i>Stem Cells</i> , 2017, 35, 248-255.	1.4	94
40	Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitis. <i>Experimental Dermatology</i> , 2017, 26, 28-35.	1.4	182
41	Atopic dermatitis: immune deviation, barrier dysfunction, IgE autoreactivity and new therapies. <i>Allergology International</i> , 2017, 66, 398-403.	1.4	202

#	ARTICLE	IF	CITATIONS
42	Changing Paradigms in the Treatment of Severe Asthma: The Role of Biologic Therapies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, S1-S14.	2.0	57
43	ERBIN deficiency links STAT3 and TGF- β 2 pathway defects with atopy in humans. <i>Journal of Experimental Medicine</i> , 2017, 214, 669-680.	4.2	70
44	Commonality of the IL-4/IL-13 pathway in atopic diseases. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 425-437.	1.3	324
45	Clinical Development of Histamine H4 Receptor Antagonists. <i>Handbook of Experimental Pharmacology</i> , 2017, 241, 301-320.	0.9	40
46	Ditching the Itch with Anti- ϵ Type 2 Cytokine Therapies for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2017, 376, 878-879.	13.9	10
47	Dupilumab in the treatment of moderate-to-severe atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 301-310.	1.3	39
48	Assessing the current treatment of atopic dermatitis: Unmet needs. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, S47-S48.	1.5	24
50	Dupilumab Use in Atopic Conditions and Its Side Effects. <i>Current Dermatology Reports</i> , 2017, 6, 43-47.	1.1	0
51	Moving toward endotypes in atopic dermatitis: Identification of patient clusters based on serum biomarker analysis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 730-737.	1.5	127
52	Management of Respiratory Symptoms Induced by Non-Steroidal Anti-Inflammatory Drugs. <i>Current Treatment Options in Allergy</i> , 2017, 4, 268-282.	0.9	0
53	Rash diagnostics. <i>Current Opinion in Pediatrics</i> , 2017, 29, 371-378.	1.0	3
54	Patient Burden of Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2017, 35, 303-316.	1.0	31
55	Biologics in patients with skin diseases. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1423-1430.	1.5	28
56	Long-term management of moderate-to-severe atopic dermatitis with dupilumab and concomitant topical corticosteroids (LIBERTY AD CHRONOS): a 1-year, randomised, double-blinded, placebo-controlled, phase 3 trial. <i>Lancet, The</i> , 2017, 389, 2287-2303.	6.3	884
57	Systemic Therapy of Atopic Dermatitis: When, How, for How Long?. <i>Current Dermatology Reports</i> , 2017, 6, 149-160.	1.1	0
58	Immunoabsorption for treatment of severe atopic dermatitis. <i>Atherosclerosis Supplements</i> , 2017, 30, 264-270.	1.2	7
59	Itch intensity in moderate-to-severe plaque psoriasis versus atopic dermatitis: A meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2017, 76, 1198-1200.e1.	0.6	16
60	The Role of Interleukins 4 and/or 13 in the Pathophysiology and Treatment of Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2017, 35, 327-334.	1.0	50

#	ARTICLE	IF	CITATIONS
61	Anti-Interleukin-31 Receptor A Antibody for Atopic Dermatitis. <i>New England Journal of Medicine</i> , 2017, 376, 2092-2093.	13.9	24
62	Adjunctive Management of Itch in Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2017, 35, 373-394.	1.0	17
63	Improving Our Understanding of Atopic Dermatitis Will Require Research Beyond Immunology and Dermatology. <i>International Journal of Toxicology</i> , 2017, 36, 185-186.	0.6	0
64	Dupilumab: First Global Approval. <i>Drugs</i> , 2017, 77, 1115-1121.	4.9	123
65	Novel concepts of prevention and treatment of atopic dermatitis through barrier and immune manipulations with implications for the atopic march. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 1723-1734.	1.5	202
66	The International TREATment of ATopic Eczema (TREAT) Registry Taskforce: An Initiative to Harmonize Data Collection across National Atopic Eczema Photo- and Systemic Therapy Registries. <i>Journal of Investigative Dermatology</i> , 2017, 137, 2014-2016.	0.3	25
67	Biologics for asthma and allergy. <i>Current Opinion in Otolaryngology and Head and Neck Surgery</i> , 2017, 25, 231-234.	0.8	11
68	The immunology of atopic dermatitis and its reversibility with broad-spectrum and targeted therapies. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, S65-S76.	1.5	453
69	Neurodermitis: Ein Register sorgt für Durchblick. <i>JDDG - Journal of the German Society of Dermatology</i> , 2017, 15, 1-3.	0.4	0
70	Atopic Eczema: Genetic Associations and Potential Links to Developmental Exposures. <i>International Journal of Toxicology</i> , 2017, 36, 187-198.	0.6	11
71	Atopic Dermatitis, Depression, and Suicidality. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 237-242.	0.6	30
72	Systemic Treatment of Adult Atopic Dermatitis: A Review. <i>Dermatology and Therapy</i> , 2017, 7, 1-23.	1.4	111
73	Dupilumab for the treatment of asthma. <i>Expert Opinion on Biological Therapy</i> , 2017, 17, 1565-1572.	1.4	33
74	The transcriptional program, functional heterogeneity, and clinical targeting of mast cells. <i>Journal of Experimental Medicine</i> , 2017, 214, 2491-2506.	4.2	88
75	Monoclonal Antibodies for Atopic Dermatitis: Progress and Potential. <i>BioDrugs</i> , 2017, 31, 409-422.	2.2	4
76	Revisiting murine models for atopic dermatitis and psoriasis with multipolar cytokine axes. <i>Current Opinion in Immunology</i> , 2017, 48, 99-107.	2.4	27
77	Sensory Neurons Co-opt Classical Immune Signaling Pathways to Mediate Chronic Itch. <i>Cell</i> , 2017, 171, 217-228.e13.	13.5	692
78	IL-4R Inhibitor for Atopic Disease. <i>Cell</i> , 2017, 170, 222.	13.5	28

#	ARTICLE	IF	CITATIONS
79	What progress have we made in the treatment of atopic eczema? Putting the new biological therapies into a wider context. <i>British Journal of Dermatology</i> , 2017, 177, 4-6.	1.4	4
80	Methotrexate for Severe Childhood Atopic Dermatitis: Clinical Experience in a Tertiary Center. <i>Pediatric Dermatology</i> , 2017, 34, 528-534.	0.5	36
81	Cicatricial ectropion in a patient treated with dupilumab. <i>American Journal of Ophthalmology Case Reports</i> , 2017, 7, 120-122.	0.4	64
82	Biologics for Itch: IL-4/IL-13, IL-31, IL-17, and IL-23 Antagonists. <i>Current Dermatology Reports</i> , 2017, 6, 263-272.	1.1	3
84	The interplay between genetic and environmental factors in the pathogenesis of atopic dermatitis. <i>Immunological Reviews</i> , 2017, 278, 246-262.	2.8	112
85	The etiopathogenesis of atopic dermatitis: barrier disruption, immunological derangement, and pruritus. <i>Inflammation and Regeneration</i> , 2017, 37, 14.	1.5	104
86	Mast cell and eosinophil surface receptors as targets for anti-allergic therapy. , 2017, 170, 37-63.		38
87	Itch in Atopic Dermatitis. <i>Immunology and Allergy Clinics of North America</i> , 2017, 37, 113-122.	0.7	56
88	Biologics targeting IL-5, IL-4 or IL-13 for the treatment of asthma – an update. <i>Expert Review of Clinical Immunology</i> , 2017, 13, 143-149.	1.3	27
89	An IL-17 – dominant immune profile is shared across the major orphan forms of ichthyosis. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 152-165.	1.5	135
90	Molecular mechanisms in atopic eczema: insights gained from genetic studies. <i>Journal of Pathology</i> , 2017, 241, 140-145.	2.1	33
91	Major differences between human atopic dermatitis and murine models, as determined by using global transcriptomic profiling. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 139, 562-571.	1.5	96
92	Circulating CLA ⁺ T cells in atopic dermatitis and their possible role as peripheral biomarkers. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2017, 72, 366-372.	2.7	40
93	Review of Systemic Treatment Options for Adult Atopic Dermatitis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2017, 21, 31-39.	0.6	42
95	Biologic Therapy for Atopic Dermatitis: Moving Beyond the Practice Parameter and Guidelines. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2017, 5, 1477-1487.	2.0	41
96	Emerging Treatment Options in Atopic Dermatitis: Systemic Therapies. <i>Dermatology</i> , 2017, 233, 344-357.	0.9	50
97	Behandeling met biologics in de dermatologie. <i>Bijblijven (Amsterdam, Netherlands)</i> , 2017, 34, 129.	0.0	0
98	Atopic dermatitis treatment: Current state of the art and emerging therapies. <i>Allergy and Asthma Proceedings</i> , 2017, 38, 243-249.	1.0	21

#	ARTICLE	IF	CITATIONS
99	The ÆAlarminsÆ•HMBG1 and IL-33 Downregulate Structural Skin Barrier Proteins and Impair Epidermal Growth. <i>Acta Dermato-Venereologica</i> , 2017, 97, 305-312.	0.6	38
100	Dupilumab in the management of moderate-to-severe asthma: the data so far. <i>Therapeutics and Clinical Risk Management</i> , 2017, Volume 13, 1139-1149.	0.9	38
101	Glycobiology of Eosinophilic Inflammation: Contributions of Siglecs, Glycans, and Other Glycan-Binding Proteins. <i>Frontiers in Medicine</i> , 2017, 4, 116.	1.2	24
102	Atopic dermatitis: the new frontier. <i>Medical Journal of Australia</i> , 2017, 207, 351-356.	0.8	22
103	Glycomacropptide Attenuates Inflammation, Pruritus, and Th2 Response Associated with Atopic Dermatitis Induced by 2,4-Dinitrochlorobenzene in Rat. <i>Journal of Immunology Research</i> , 2017, 2017, 1-11.	0.9	19
104	New Modalities in the Treatment of Refractory Alopecia Areata. , 2017, , .		1
105	Direct-Access Online Care for the Management of Atopic Dermatitis: A Randomized Clinical Trial Examining Patient Quality of Life. <i>Telemedicine Journal and E-Health</i> , 2017, 23, 726-732.	1.6	24
106	Spotlight on dupilumab in the treatment of atopic dermatitis: design, development, and potential place in therapy. <i>Drug Design, Development and Therapy</i> , 2017, Volume 11, 1473-1480.	2.0	25
107	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults. <i>Oncotarget</i> , 2017, 8, 108480-108491.	0.8	10
108	Dupilumab: A review of its use in the treatment of atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, S28-S36.	0.6	218
109	Dupilumab treatment in moderate-to-severe atopic dermatitis: A systematic review and meta-analysis. <i>Journal of Dermatological Science</i> , 2018, 90, 190-198.	1.0	66
110	Cutaneous Manifestations of Reactions to Biologics. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 12.	2.4	6
111	<i>Pinus densiflora</i> bark extract ameliorates 2,4-dinitrochlorobenzene-induced atopic dermatitis in NC/Nga mice by regulating Th1/Th2 balance and skin barrier function. <i>Phytotherapy Research</i> , 2018, 32, 1135-1143.	2.8	17
112	Uses of biologics in allergic diseases. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 357-366.	0.5	24
113	Interactions of the immune and sensory nervous systems in atopy. <i>FEBS Journal</i> , 2018, 285, 3138-3151.	2.2	34
114	Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trial. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 872-881.e6.	0.6	265
115	Efficacy and safety of lebrikizumab (an anti-IL-13 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by topical corticosteroids: A randomized, placebo-controlled phase II trial (TREBLE). <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 863-871.e11.	0.6	267
116	Dupilumab para el tratamiento de la dermatitis atÁpica. <i>Actas Dermo-sifiliogrÁficas</i> , 2018, 109, 230-240.	0.2	11

#	ARTICLE	IF	CITATIONS
117	Potential Risks Related to Modulating Interleukin-13 and Interleukin-4 Signalling: A Systematic Review. <i>Drug Safety</i> , 2018, 41, 489-509.	1.4	41
118	Clinical approach to the patient with refractory atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 23-33.e1.	0.5	17
119	Impacto económico de la dermatitis atópica en adultos: estudio de base poblacional (estudio IDEA). <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 35-46.	0.2	30
120	Economic Impact of Atopic Dermatitis in Adults: A Population-Based Study (IDEA Study). <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 35-46.	0.2	9
121	Atopic dermatitis yardstick: Practical recommendations for an evolving therapeutic landscape. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 10-22.e2.	0.5	214
122	Biologics for the Treatment of Atopic Dermatitis. , 2018, , 309-317.		0
123	Immunomodulating Agents as Antipruritics. <i>Dermatologic Clinics</i> , 2018, 36, 325-334.	1.0	18
124	Precision Medicine in Chronic Rhinosinusitis with Nasal Polyps. <i>Current Allergy and Asthma Reports</i> , 2018, 18, 25.	2.4	71
125	Dupilumab for treatment of atopic dermatitis. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 467-474.	1.3	135
126	Dupilumab for the Treatment of Atopic Dermatitis. <i>Actas Dermo-sifiligráficas</i> , 2018, 109, 230-240.	0.2	6
127	Interleukin-31 and interleukin-31 receptor: New therapeutic targets for atopic dermatitis. <i>Experimental Dermatology</i> , 2018, 27, 327-331.	1.4	109
128	Basophil-derived IL-4 promotes epicutaneous antigen sensitization concomitant with the development of food allergy. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 223-234.e5.	1.5	119
129	A novel JAK inhibitor JTE-052 reduces skin inflammation and ameliorates chronic dermatitis in rodent models: Comparison with conventional therapeutic agents. <i>Experimental Dermatology</i> , 2018, 27, 22-29.	1.4	46
130	Are Biologics Efficacious in Atopic Dermatitis? A Systematic Review and Meta-Analysis. <i>American Journal of Clinical Dermatology</i> , 2018, 19, 145-165.	3.3	64
131	Changing perspectives in atopic dermatitis. <i>Allergologia Et Immunopathologia</i> , 2018, 46, 397-412.	1.0	14
132	Risk of infection in patients with atopic dermatitis treated with dupilumab: A meta-analysis of randomized controlled trials. <i>Journal of the American Academy of Dermatology</i> , 2018, 78, 62-69.e1.	0.6	104
133	Novel Therapeutic Approaches to Atopic Dermatitis. <i>Archivum Immunologiae Et Therapiae Experimentalis</i> , 2018, 66, 171-181.	1.0	13
134	Dupilumab treatment improves quality of life in adult patients with moderate-to-severe atopic dermatitis: results from a randomized, placebo-controlled clinical trial. <i>British Journal of Dermatology</i> , 2018, 178, 406-414.	1.4	52

#	ARTICLE	IF	CITATIONS
135	New and emerging targeted systemic therapies: a new era for atopic dermatitis. <i>Journal of Dermatological Treatment</i> , 2018, 29, 364-374.	1.1	38
136	Adverse events of Dupilumab in adults with moderate-to-severe atopic dermatitis: A meta-analysis. <i>International Immunopharmacology</i> , 2018, 54, 303-310.	1.7	97
137	Dupilumab with concomitant topical corticosteroid treatment in adults with atopic dermatitis with an inadequate response or intolerance to ciclosporin A or when this treatment is medically inadvisable: a placebo-controlled, randomized phase III clinical t. <i>British Journal of Dermatology</i> , 2018, 178, 1083-1101.	1.4	380
139	Diagnosis and Management of Conjunctivitis for the Dermatologist. <i>Journal of Cutaneous Medicine and Surgery</i> , 2018, 22, 200-206.	0.6	25
140	New and Future Therapies. , 2018, , 329-342.		0
141	Cytokine Network. , 2018, , 97-112.		1
142	Quality assessment of atopic dermatitis clinical practice guidelines in 18 years. <i>Archives of Dermatological Research</i> , 2018, 310, 29-37.	1.1	4
143	Immunologic, microbial, and epithelial interactions in atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2018, 120, 34-41.	0.5	120
144	Efficacy and safety of dupilumab for the treatment of moderate-to-severe atopic dermatitis in adults: A pooled analysis of two phase 2 clinical trials. <i>Journal of the American Association of Nurse Practitioners</i> , 2018, 30, 529-541.	0.5	11
146	Management of Severe Asthma in Children. <i>Current Treatment Options in Pediatrics</i> , 2018, 4, 438-455.	0.2	0
147	The Itch-Scratch Cycle: A Neuroimmune Perspective. <i>Trends in Immunology</i> , 2018, 39, 980-991.	2.9	135
148	Pathomechanism of skin-originated allergic diseases. <i>Immunological Medicine</i> , 2018, 41, 170-176.	1.4	3
149	Biological therapies for atopic dermatitis: An update (Review). <i>Experimental and Therapeutic Medicine</i> , 2019, 17, 1061-1067.	0.8	47
151	Anti-Atopic Properties of Gracillin Isolated from <i>Dioscorea quinqueloba</i> on 2,4-Dinitrochlorobenzene-Induced Skin Lesions in Mice. <i>Nutrients</i> , 2018, 10, 1205.	1.7	14
152	Eosinophils Determine Dermal Thickening and Water Loss in an MC903 Model of Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2018, 138, 2606-2616.	0.3	39
153	Recent developments in the use of biologics targeting IL-5, IL-4, or IL-13 in severe refractory asthma. <i>Expert Review of Respiratory Medicine</i> , 2018, 12, 957-963.	1.0	10
154	Systemic immunomodulatory treatments for atopic dermatitis: protocol for a systematic review with network meta-analysis. <i>BMJ Open</i> , 2018, 8, e023061.	0.8	12
156	Dupilumab Efficacy and Safety in Moderate-to-Severe Uncontrolled Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2486-2496.	13.9	1,253

#	ARTICLE	IF	CITATIONS
157	Efficacy and Safety of Dupilumab in Glucocorticoid-Dependent Severe Asthma. <i>New England Journal of Medicine</i> , 2018, 378, 2475-2485.	13.9	816
158	Consensus-based European guidelines for treatment of atopic eczema (atopic dermatitis) in adults and children: part II. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2018, 32, 850-878.	1.3	519
159	After the approval of dupilumab for moderate-to-severe atopic dermatitis: what is next on the research agenda?. <i>British Journal of Dermatology</i> , 2018, 178, 992-993.	1.4	1
160	Dupilumab: A New Paradigm for the Treatment of Allergic Diseases. <i>Journal of Investigational Allergology and Clinical Immunology</i> , 2018, 28, 139-150.	0.6	85
161	Cytokine modulation of atopic itch. <i>Current Opinion in Immunology</i> , 2018, 54, 7-12.	2.4	44
162	Profile of dupilumab and its potential in the treatment of inadequately controlled moderate-to-severe atopic dermatitis. <i>Clinical, Cosmetic and Investigational Dermatology</i> , 2018, Volume 11, 41-49.	0.8	12
163	Investigational drugs for atopic dermatitis. <i>Expert Opinion on Investigational Drugs</i> , 2018, 27, 637-647.	1.9	10
164	Is IgE or eosinophils the key player in allergic asthma pathogenesis? Are we asking the right question?. <i>Respiratory Research</i> , 2018, 19, 113.	1.4	139
165	Dupilumab: an evidence-based review of its potential in the treatment of atopic dermatitis. <i>Core Evidence</i> , 2018, Volume 13, 13-20.	4.7	41
166	Adult atopic dermatitis: new and emerging therapies. <i>Expert Review of Clinical Pharmacology</i> , 2018, 11, 867-878.	1.3	20
167	Irradiation with 310 nm and 340 nm ultraviolet light-emitting-diodes can improve atopic dermatitis-like skin lesions in NC/Nga mice. <i>Photochemical and Photobiological Sciences</i> , 2018, 17, 1127-1135.	1.6	5
168	Dupilumab in atopic dermatitis: rationale, latest evidence and place in therapy. <i>Therapeutic Advances in Chronic Disease</i> , 2018, 9, 159-170.	1.1	25
169	Significance of Skin Barrier Dysfunction in Atopic Dermatitis. <i>Allergy, Asthma and Immunology Research</i> , 2018, 10, 207.	1.1	228
170	Therapeutic Targeting of the Interleukin-4/Interleukin-13 Signaling Pathway: In Allergy and Beyond. <i>BioDrugs</i> , 2018, 32, 201-220.	2.2	46
172	Mechanistic insights into topical tacrolimus for the treatment of atopic dermatitis. <i>Pediatric Allergy and Immunology</i> , 2018, 29, 233-238.	1.1	32
173	Monoclonal antibodies for the treatment of atopic dermatitis. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2018, 18, 356-364.	1.1	10
174	Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor. <i>JAAD Case Reports</i> , 2018, 4, 515-517.	0.4	18
175	The biodiversity hypothesis and immunotolerance in allergy. <i>Allergo Journal International</i> , 2018, 27, 140-146.	0.9	4

#	ARTICLE	IF	CITATIONS
176	Cytokines and Cytokine Receptors. , 2019, , 127-155.e1.		44
177	Atopic dermatitis: the skin barrier and beyond. British Journal of Dermatology, 2019, 180, 464-474.	1.4	156
178	Atopic and Contact Dermatitis. , 2019, , 611-624.e1.		1
179	Treatment of atopic dermatitis with tralokinumab, an anti-IL-13 mAb. Journal of Allergy and Clinical Immunology, 2019, 143, 135-141.	1.5	294
180	Novel topical and systemic therapies in atopic dermatitis. Immunological Medicine, 2019, 42, 84-93.	1.4	24
181	Dupilumab in Atopic Dermatitis. Current Treatment Options in Allergy, 2019, 6, 211-225.	0.9	2
182	New and Emerging Therapies for Pediatric Atopic Dermatitis. Paediatric Drugs, 2019, 21, 239-260.	1.3	29
183	Phenotypes and endotypes of adult asthma: Moving toward precision medicine. Journal of Allergy and Clinical Immunology, 2019, 144, 1-12.	1.5	270
184	Interleukin 9 alterations linked to alzheimer disease in african americans. Annals of Neurology, 2019, 86, 407-418.	2.8	42
185	Pathophysiology of Atopic Dermatitis and Psoriasis: Implications for Management in Children. Children, 2019, 6, 108.	0.6	31
186	Endotype-driven precision medicine in chronic rhinosinusitis. Expert Review of Clinical Immunology, 2019, 15, 1171-1183.	1.3	28
187	Roles of YcfR in Biofilm Formation in <i>Salmonella</i> Typhimurium ATCC 14028. Molecular Plant-Microbe Interactions, 2019, 32, 708-716.	1.4	12
188	Dupilumab reduces opacification across all sinuses and related symptoms in patients with CRSwNP. Rhinology, 2019, 58, 0-0.	0.7	21
189	Proof-of-concept clinical trial of etokimab shows a key role for IL-33 in atopic dermatitis pathogenesis. Science Translational Medicine, 2019, 11, .	5.8	172
190	Efficacy and safety of dupilumab in patients with severe chronic rhinosinusitis with nasal polyps (LIBERTY NP SINUS-24 and LIBERTY NP SINUS-52): results from two multicentre, randomised, double-blind, placebo-controlled, parallel-group phase 3 trials. Lancet, The, 2019, 394, 1638-1650.	6.3	812
191	Dupilumab-associated blepharoconjunctivitis. American Journal of Ophthalmology Case Reports, 2019, 16, 100550.	0.4	19
192	Crisaborole and atopic dermatitis skin biomarkers: An inpatient randomized trial. Journal of Allergy and Clinical Immunology, 2019, 144, 1274-1289.	1.5	82
193	Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis. Children, 2019, 6, 103.	0.6	18

#	ARTICLE	IF	CITATIONS
194	Dupilumab utility in difficult-to-treat asthma. <i>Immunotherapy</i> , 2019, 11, 261-264.	1.0	1
195	Current and emerging biologic and small molecule therapies for atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 367-380.	1.4	19
196	Future trends in the treatment of atopic dermatitis. <i>Immunological Medicine</i> , 2019, 42, 10-15.	1.4	12
197	Potential Mechanisms of T Cell-Mediated and Eosinophil-Independent Bronchial Hyperresponsiveness. <i>International Journal of Molecular Sciences</i> , 2019, 20, 2980.	1.8	14
198	Consensus on the therapeutic management of atopic dermatitis - Brazilian Society of Dermatology. <i>Anais Brasileiros De Dermatologia</i> , 2019, 94, 67-75.	0.5	22
199	Infections in Dupilumab Clinical Trials in Atopic Dermatitis: A Comprehensive Pooled Analysis. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 443-456.	3.3	130
200	Dupilumab improves asthma outcomes irrespective of frequency of previous asthma exacerbation history. <i>Annals of Allergy, Asthma and Immunology</i> , 2019, 123, 222-224.e1.	0.5	14
201	The Cytokines of Asthma. <i>Immunity</i> , 2019, 50, 975-991.	6.6	622
202	Efficacy and safety of dupilumab monotherapy in adults with moderate-to-severe atopic dermatitis: a pooled analysis of two phase 3 randomized trials (LIBERTY AD SOLO 1 and LIBERTY AD SOLO 2). <i>Journal of Dermatological Science</i> , 2019, 94, 266-275.	1.0	121
203	Pathophysiology of atopic dermatitis: Clinical implications. <i>Allergy and Asthma Proceedings</i> , 2019, 40, 84-92.	1.0	300
204	Th9 Cells in Allergic Disease. <i>Current Allergy and Asthma Reports</i> , 2019, 19, 29.	2.4	34
205	Conjunctivitis in dupilumab clinical trials. <i>British Journal of Dermatology</i> , 2019, 181, 459-473.	1.4	288
206	Optimization of placebo use in clinical trials with systemic treatments for atopic dermatitis: an International Eczema Council survey-based position statement. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 807-815.	1.3	15
207	Fifty-two week follow-up safety and effectiveness results of dupilumab treatment of moderate-to-severe atopic dermatitis from a retrospective, multicentric series. <i>Dermatologic Therapy</i> , 2019, 32, e12931.	0.8	26
208	European S2k Guideline on Chronic Pruritus. <i>Acta Dermato-Venereologica</i> , 2019, 99, 469-506.	0.6	211
209	What's New in Atopic Dermatitis. <i>Dermatologic Clinics</i> , 2019, 37, 205-213.	1.0	48
210	Towards personalized treatment in atopic dermatitis. <i>Expert Opinion on Biological Therapy</i> , 2019, 19, 469-476.	1.4	12
211	Peak Pruritus Numerical Rating Scale: psychometric validation and responder definition for assessing itch in moderate-to-severe atopic dermatitis. <i>British Journal of Dermatology</i> , 2019, 181, 761-769.	1.4	193

#	ARTICLE	IF	CITATIONS
212	Tezepelumab, an anti-IL-13 thymic stromal lymphopoietin monoclonal antibody, in the treatment of moderate to severe atopic dermatitis: A randomized phase 2a clinical trial. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 1013-1021.	0.6	222
213	A review of dupilumab in the treatment of atopic diseases. <i>Human Vaccines and Immunotherapeutics</i> , 2019, 15, 2129-2139.	1.4	53
215	A Clinician's Guide to the Recognition and Management of Dupilumab-Associated Conjunctivitis. <i>Drugs in R and D</i> , 2019, 19, 311-318.	1.1	39
217	IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. <i>Journal of Autoimmunity</i> , 2019, 96, 104-112.	3.0	85
218	Dupilumab does not affect correlates of vaccine-induced immunity: A randomized, placebo-controlled trial in adults with moderate-to-severe atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 158-167.e1.	0.6	99
219	Dermatology today and tomorrow: from symptom control to targeted therapy. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 3-36.	1.3	31
220	Interleukin-31-mediated photoablation of pruritogenic epidermal neurons reduces itch-associated behaviours in mice. <i>Nature Biomedical Engineering</i> , 2019, 3, 114-125.	11.6	18
221	An update on the topical and oral therapy options for treating pediatric atopic dermatitis. <i>Expert Opinion on Pharmacotherapy</i> , 2019, 20, 621-629.	0.9	12
222	Atopic dermatitis: a review of evolving targeted therapies. <i>Expert Review of Clinical Immunology</i> , 2019, 15, 275-288.	1.3	16
223	Dupilumab progressively improves systemic and cutaneous abnormalities in patients with atopic dermatitis. <i>Journal of Allergy and Clinical Immunology</i> , 2019, 143, 155-172.	1.5	436
224	IgE-specific immunoadsorption: New treatment option for severe refractory atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2019, 74, 1190-1193.	2.7	5
225	Current pharmaceutical developments in atopic dermatitis. <i>Current Opinion in Pharmacology</i> , 2019, 46, 7-13.	1.7	26
226	Relative efficacy of systemic treatments for atopic dermatitis. <i>Journal of the American Academy of Dermatology</i> , 2019, 80, 411-416.e4.	0.6	30
227	JAK Inhibitors for Atopic Dermatitis: An Update. <i>American Journal of Clinical Dermatology</i> , 2019, 20, 181-192.	3.3	158
228	Interleukin-13: Targeting an underestimated cytokine in atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 54-62.	2.7	215
229	Dupilumab improves patient-reported symptoms of atopic dermatitis, symptoms of anxiety and depression, and health-related quality of life in moderate-to-severe atopic dermatitis: analysis of pooled data from the randomized trials SOLO 1 and SOLO 2. <i>Journal of Dermatological Treatment</i> , 2020, 31, 606-614.	1.1	72
230	Dupilumab Efficacy in Uncontrolled, Moderate-to-Severe Asthma with Self-Reported Chronic Rhinosinusitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 527-539.e9.	2.0	45
231	Dupilumab shows long-term safety and efficacy in patients with moderate to severe atopic dermatitis enrolled in a phase 3 open-label extension study. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 377-388.	0.6	155

#	ARTICLE	IF	CITATIONS
232	Exploring changes in placebo treatment arms in hidradenitis suppurativa randomized clinical trials: A systematic review. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 45-53.	0.6	13
233	Dupilumab Efficacy in Patients with Uncontrolled, Moderate-to-Severe Allergic Asthma. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2020, 8, 516-526.	2.0	123
234	New treatments for atopic dermatitis targeting beyond IL-4/IL-13 cytokines. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 124, 28-35.	0.5	102
235	Efficacy of Dupilumab in a Phase 2 Randomized Trial of Adults With Active Eosinophilic Esophagitis. <i>Gastroenterology</i> , 2020, 158, 111-122.e10.	0.6	300
236	Dupilumab in adolescents with uncontrolled moderate-to-severe atopic dermatitis: results from a phase II a open-label trial and subsequent phase III open-label extension. <i>British Journal of Dermatology</i> , 2020, 182, 85-96.	1.4	111
237	Placebo responses in randomized controlled trials for systemic therapy in atopic dermatitis: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 62-71.	0.6	19
238	Laboratory safety of dupilumab in moderate-to-severe atopic dermatitis: results from three phase III trials (LIBERTY AD SOLO 1, LIBERTY AD SOLO 2, LIBERTY AD CHRONOS). <i>British Journal of Dermatology</i> , 2020, 182, 1120-1135.	1.4	92
239	IL-4R α Blockade by Dupilumab Decreases <i>Staphylococcus aureus</i> Colonization and Increases Microbial Diversity in Atopic Dermatitis. <i>Journal of Investigative Dermatology</i> , 2020, 140, 191-202.e7.	0.3	130
240	Mycophenolate mofetil and atopic dermatitis: systematic review and meta-analysis. <i>Journal of Dermatological Treatment</i> , 2020, 31, 810-814.	1.1	27
241	Dupilumab improves health-related quality of life in patients with chronic rhinosinusitis with nasal polyposis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 148-157.	2.7	75
242	New biological treatments for asthma and skin allergies. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 546-560.	2.7	70
243	Neuroimmune interactions in chronic itch of atopic dermatitis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 239-250.	1.3	98
244	Efficacy and Safety of Dupilumab in Adolescents With Uncontrolled Moderate to Severe Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 44.	2.0	297
245	Baseline characteristics, disease severity and treatment history of patients with atopic dermatitis included in the German AD Registry TREATgermany. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1263-1272.	1.3	41
246	Efficacy and safety of dupilumab in Japanese adults with moderate-to-severe atopic dermatitis: a subanalysis of three clinical trials. <i>British Journal of Dermatology</i> , 2020, 183, 39-51.	1.4	27
247	Kallikrein 7 Promotes Atopic Dermatitis-Associated Itch Independently of Skin Inflammation. <i>Journal of Investigative Dermatology</i> , 2020, 140, 1244-1252.e4.	0.3	36
248	Hold the device against the skin: the impact of injection duration on user's force for handheld autoinjectors. <i>Expert Opinion on Drug Delivery</i> , 2020, 17, 225-236.	2.4	15
249	Efficacy and Safety of Multiple Dupilumab Dose Regimens After Initial Successful Treatment in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 131.	2.0	110

#	ARTICLE	IF	CITATIONS
250	Placebo response in phase 2 and 3 trials of systemic and biological therapies for atopic dermatitis—a systematic review and meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1143-1150.	1.3	10
251	The effect of dupilumab on lung function parameters in patients with oral corticosteroid-dependent severe asthma. <i>Respiratory Medicine: X</i> , 2020, 2, 100010.	1.4	3
252	Dual blockade of IL-4 and IL-13 with dupilumab, an IL-4R α antibody, is required to broadly inhibit type 2 inflammation. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2020, 75, 1188-1204.	2.7	209
253	Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical Trial. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 119-131.	3.3	56
254	Efficacy and safety of indigo naturalis ointment in Treating Atopic Dermatitis: A randomized clinical trial. <i>Journal of Ethnopharmacology</i> , 2020, 250, 112477.	2.0	14
255	Biologics in Children with Allergic Diseases. <i>Current Pediatric Reviews</i> , 2020, 16, 140-147.	0.4	16
256	Upadacitinib in adults with moderate to severe atopic dermatitis: 16-week results from a randomized, placebo-controlled trial. <i>Journal of Allergy and Clinical Immunology</i> , 2020, 145, 877-884.	1.5	242
257	Response to R. Waldman et al.: “Does IL-4 inhibition play a role in dupilumab-associated conjunctivitis?” <i>British Journal of Dermatology</i> , 2020, 182, 1310-1312.	1.4	1
258	Applications of Human Skin Microbiota in the Cutaneous Disorders for Ecology-Based Therapy. <i>Frontiers in Cellular and Infection Microbiology</i> , 2020, 10, 570261.	1.8	22
259	Advances in Understanding the Initial Steps of Pruritoceptive Itch: How the Itch Hits the Switch. <i>International Journal of Molecular Sciences</i> , 2020, 21, 4883.	1.8	24
260	ETFAD/EADV Eczema task force 2020 position paper on diagnosis and treatment of atopic dermatitis in adults and children. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 2717-2744.	1.3	220
261	SnapshotDx Quiz: September 2020. <i>Journal of Investigative Dermatology</i> , 2020, 140, e97-e102.	0.3	0
262	Corneal ulceration associated with dupilumab use in a patient with atopic dermatitis. <i>American Journal of Ophthalmology Case Reports</i> , 2020, 19, 100848.	0.4	15
263	Real-world experience of dupilumab in the treatment of moderate-to-severe atopic dermatitis. <i>International Journal of Dermatology</i> , 2020, 59, e361-e363.	0.5	5
264	Selective JAK1 Inhibitors for the Treatment of Atopic Dermatitis: Focus on Upadacitinib and Abrocitinib. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 783-798.	3.3	73
265	Dupilumab for the treatment of adolescents with atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2020, 16, 641-650.	1.3	12
266	Dupilumab use in atopic dermatitis and beyond in skin diseases. <i>Immunotherapy</i> , 2020, 12, 1221-1235.	1.0	9
268	Systemic treatments for eczema: a network meta-analysis. <i>The Cochrane Library</i> , 2020, 2020, CD013206.	1.5	23

#	ARTICLE	IF	CITATIONS
269	Î³Î´ T cells and inflammatory skin diseases. <i>Immunological Reviews</i> , 2020, 298, 61-73.	2.8	23
270	Inclusion of Older Adults in Randomized Clinical Trials for Systemic Medications for Atopic Dermatitis. <i>JAMA Dermatology</i> , 2020, 156, 1240.	2.0	24
271	Shrinkage Estimation for Dose-Response Modeling in Phase II Trials With Multiple Schedules. <i>Statistics in Biopharmaceutical Research</i> , 2020, , 1-13.	0.6	0
273	Efficacy of dupilumab on clinical outcomes in patients with asthma and perennial allergic rhinitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2020, 125, 565-576.e1.	0.5	40
274	Dupilumab for treatment of refractory prurigo nodularis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2020, 18, 618-624.	0.4	12
276	Dupilumab Provides Favorable Safety and Sustained Efficacy for up to 3 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2020, 21, 567-577.	3.3	78
277	Infectious Implications of Interleukin-1, Interleukin-6, and T Helper Type 2 Inhibition. <i>Infectious Disease Clinics of North America</i> , 2020, 34, 211-234.	1.9	10
278	Immune Modulation in Asthma: Current Concepts and Future Strategies. <i>Respiration</i> , 2020, 99, 566-576.	1.2	16
279	Infectious Complications of Biological and Small Molecule Targeted Immunomodulatory Therapies. <i>Clinical Microbiology Reviews</i> , 2020, 33, .	5.7	68
280	Dupilumab treatment results in early and sustained improvements in itch in adolescents and adults with moderate to severe atopic dermatitis: Analysis of the randomized phase 3 studies SOLO 1 and SOLO 2, AD ADOL, and CHRONOS. <i>Journal of the American Academy of Dermatology</i> , 2020, 82, 1328-1336.	0.6	74
281	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab Using Phase 3 Data. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 756-767.	0.8	10
282	Blood natural killer cell deficiency reveals an immunotherapy strategy for atopic dermatitis. <i>Science Translational Medicine</i> , 2020, 12, .	5.8	57
283	An overview of drug discovery efforts for eczema: why is this itch so difficult to scratch?. <i>Expert Opinion on Drug Discovery</i> , 2020, 15, 487-498.	2.5	7
284	Fermented <i>Morinda citrifolia</i> (Noni) Alleviates DNCB-Induced Atopic Dermatitis in NC/Nga Mice through Modulating Immune Balance and Skin Barrier Function. <i>Nutrients</i> , 2020, 12, 249.	1.7	30
285	Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Dupilumab in Healthy Adult Subjects. <i>Clinical Pharmacology in Drug Development</i> , 2020, 9, 742-755.	0.8	36
286	Pairwise indirect treatment comparison of dupilumab versus other biologics in patients with uncontrolled persistent asthma. <i>Respiratory Medicine</i> , 2022, 191, 105991.	1.3	13
287	Alopecia areata development in atopic dermatitis patients treated with dupilumab. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, e612-e613.	1.3	17
288	Dupilumab improves lung function in patients with uncontrolled, moderate-to-severe asthma. <i>ERJ Open Research</i> , 2020, 6, 00204-2019.	1.1	36

#	ARTICLE	IF	CITATIONS
289	New and emerging treatments for inflammatory itch. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 13-20.	0.5	49
290	Confirmation of multiple endotypes in atopic dermatitis based on serum biomarkers. <i>Journal of Allergy and Clinical Immunology</i> , 2021, 147, 189-198.	1.5	61
291	Dupilumab significantly improves sleep outcomes in adult patients with atopic dermatitis: results from five randomized clinical trials. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, e130-e133.	1.3	7
292	Efficacy and safety of dupilumab for moderate-to-severe atopic dermatitis: A systematic review for the EAACI biologicals guidelines. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 45-58.	2.7	41
293	Real-world persistence with dupilumab among adults with atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2021, 126, 40-45.	0.5	31
294	Systemic treatments in the management of atopic dermatitis: A systematic review and meta-analysis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 1053-1076.	2.7	66
295	A position paper on the management of itch and pain in atopic dermatitis from the International Society of Atopic Dermatitis (ISAD)/Oriented Patient Education Network in Dermatology (OPENED) task force. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 787-796.	1.3	30
296	Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: A propensity score-matched cohort study. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 300-311.	0.6	20
297	Therapeutic targeting of the IL-13 pathway in skin inflammation. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 15-25.	1.3	16
298	Biologics for Treatment of Atopic Dermatitis: Current Status and Future Prospect. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2021, 9, 1053-1065.	2.0	68
299	Real-world evidence of dupilumab efficacy and risk of adverse events: A systematic review and meta-analysis. <i>Journal of the American Academy of Dermatology</i> , 2021, 84, 139-147.	0.6	149
300	Update of Systemic treatment of atopic dermatitis of the S2k guideline on atopic dermatitis. <i>JDDG - Journal of the German Society of Dermatology</i> , 2021, 19, 151-168.	0.4	30
301	A new era has begun: Treatment of atopic dermatitis with biologics. <i>Allergologie Select</i> , 2021, 5, 265-273.	1.6	10
302	Allergen Immunotherapy for Atopic Dermatitis. , 2021, , 221-234.		0
303	Profiling transcriptomic changes and signaling pathways in atopic dermatitis by integrative analyses on multiple databases. <i>Molecular Genetics and Genomics</i> , 2021, 296, 341-353.	1.0	1
304	Ocular surface disease associated with dupilumab treatment for atopic diseases. <i>Ocular Surface</i> , 2021, 19, 151-156.	2.2	30
306	Pharmacokinetic characterization of drugs and new product development. , 2021, , 195-277.		2
307	Eczema and Psychodermatology. , 2021, , 105-123.		0

#	ARTICLE	IF	CITATIONS
308	Serum IgE reduction and paradoxical eosinophilia associated with allergic conjunctivitis after dupilumab therapy. <i>Journal of Ophthalmic Inflammation and Infection</i> , 2021, 11, 3.	1.2	14
309	Intractable Itch in Atopic Dermatitis: Causes and Treatments. <i>Biomedicines</i> , 2021, 9, 229.	1.4	15
310	Aspirin exacerbated respiratory disease (AERD): molecular and cellular diagnostic & prognostic approaches. <i>Molecular Biology Reports</i> , 2021, 48, 2703-2711.	1.0	2
311	Modulating Th2 Cell Immunity for the Treatment of Asthma. <i>Frontiers in Immunology</i> , 2021, 12, 637948.	2.2	84
312	Innate lymphoid cells: The missing part of a puzzle in food allergy. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 2002-2016.	2.7	18
313	IL-13 antagonists in the treatment of atopic dermatitis. <i>Immunotherapy</i> , 2021, 13, 327-344.	1.0	5
314	Editorial: Skin Autoimmunity. <i>Frontiers in Immunology</i> , 2021, 12, 627565.	2.2	1
315	Pathogenesis of atopic dermatitis: Current concepts. <i>Journal of Skin and Sexually Transmitted Diseases</i> , 0, .	0.0	0
316	Qingxue jiedu formulation ameliorated DNFB-induced atopic dermatitis by inhibiting STAT3/MAPK/NF- κ B signaling pathways. <i>Journal of Ethnopharmacology</i> , 2021, 270, 113773.	2.0	32
317	Classification of Distinct Endotypes in Human Skin Scarring: S.C.A.R.â€”A Novel Perspective on Dermal Fibrosis. <i>Advances in Wound Care</i> , 2021, , .	2.6	5
318	Production of IL-31 in CD45RO+CLA+H4R+ T Cells in Atopic Dermatitis. <i>Journal of Clinical Medicine</i> , 2021, 10, 1976.	1.0	2
319	Current State of Monoclonal Antibody Therapy for Allergic Diseases. <i>Engineering</i> , 2021, 7, 1552-1552.	3.2	9
320	Biology and therapeutic potential of human innate lymphoid cells. <i>FEBS Journal</i> , 2022, 289, 3967-3981.	2.2	8
321	Experimental Drugs with the Potential to Treat Atopic Eczema. <i>Journal of Experimental Pharmacology</i> , 2021, Volume 13, 487-498.	1.5	2
322	Comparative efficacy and safety of systemic therapies used in moderate-to-severe atopic dermatitis: a systematic literature review and network meta-analysis. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2021, 35, 1797-1810.	1.3	67
323	Patient Reported Outcome Measure in Atopic Dermatitis Patients Treated with Dupilumab: 52-Weeks Results. <i>Life</i> , 2021, 11, 617.	1.1	0
324	Base and Covariate Population Pharmacokinetic Analyses of Dupilumab in Adolescents and Children 6 to <12 Years of Age Using Phase 3 Data. <i>Clinical Pharmacology in Drug Development</i> , 2021, 10, 1345-1357.	0.8	4
325	The IL-4, IL-13 and IL-31 pathways in atopic dermatitis. <i>Expert Review of Clinical Immunology</i> , 2021, 17, 835-852.	1.3	64

#	ARTICLE	IF	CITATIONS
326	Effect of exacerbation history on clinical response to dupilumab in moderate-to-severe uncontrolled asthma. <i>European Respiratory Journal</i> , 2021, 58, 2004498.	3.1	9
327	Effectiveness of tacrolimus ointment on facial lesions refractory to topical corticosteroid in patients with atopic dermatitis receiving dupilumab. <i>Journal of Cutaneous Immunology and Allergy</i> , 2022, 5, 17-21.	0.2	1
328	Complications oculaires induites par le dupilumab au cours du traitement de la dermatite atopique. <i>Revue Francaise D'allergologie</i> , 2021, 61, 592-592.	0.1	0
329	Short-Term Effectiveness and Safety of Biologics and Small Molecule Drugs for Moderate to Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis. <i>Life</i> , 2021, 11, 927.	1.1	13
330	A Literature Review of Real-World Effectiveness and Safety of Dupilumab for Atopic Dermatitis. <i>JID Innovations</i> , 2021, 1, 100042.	1.2	40
331	Case Report: Dupilumab Successfully Controls Severe Eczema in a Child With Elevated IgE Levels and Recurrent Skin Infections. <i>Frontiers in Pediatrics</i> , 2021, 9, 646997.	0.9	6
332	Dupilumab pharmacokinetics in Chinese healthy subjects and patients with atopic dermatitis: Results of two randomized, double-blind, placebo-controlled studies. <i>International Immunopharmacology</i> , 2021, 99, 107985.	1.7	2
333	Real Clinical Practice Data of Monthly Dupilumab Therapy in Adult Patients With Moderate-to-Severe Atopic Dermatitis: Clinical Efficacy and Predictive Markers for a Favorable Clinical Response. <i>Allergy, Asthma and Immunology Research</i> , 2021, 13, 733.	1.1	16
334	Skin Barrier-Related Pathogenesis of Atopic Dermatitis. , 2021, , 75-83.		0
335	Conjunctivitis in Dupilumab Clinical Trials for Adolescents with Atopic Dermatitis or Asthma. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 101-115.	3.3	32
336	Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 LIBERTY ASTHMA QUEST study. <i>Allergology International</i> , 2020, 69, 578-587.	1.4	14
337	Efficacy and safety of dupilumab for the treatment of adult atopic dermatitis: A meta-analysis of randomized clinical trials. <i>Journal of Allergy and Clinical Immunology</i> , 2017, 140, 888-891.e6.	1.5	53
338	Atopic dermatitis phenotypes and the need for personalized medicine. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2017, 17, 309-315.	1.1	111
339	Dupilumab Significantly Modulates Pain and Discomfort in Patients With Atopic Dermatitis: A Post Hoc Analysis of 5 Randomized Clinical Trials. <i>Dermatitis</i> , 2021, 32, S81-S91.	0.8	7
340	EAACI Biologicals Guidelines – dupilumab for children and adults with moderate-to-severe atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2021, 76, 988-1009.	2.7	24
341	Epithelial barrier repair and prevention of allergy. <i>Journal of Clinical Investigation</i> , 2019, 129, 1463-1474.	3.9	137
342	Novel systemic therapies in atopic dermatitis: what do we need to fulfil the promise of a treatment revolution?. <i>F1000Research</i> , 2019, 8, 132.	0.8	11
343	Atopic dermatitis: emerging therapies. <i>Seminars in Cutaneous Medicine and Surgery</i> , 2017, 36, 124-130.	1.6	7

#	ARTICLE	IF	CITATIONS
344	Atopic dermatitis: recent insight on pathogenesis and novel therapeutic target. Asian Pacific Journal of Allergy and Immunology, 2016, 34, 98-108.	0.2	25
345	CURRENT CONCEPTS OF ATOPIC DERMATITIS IN CHILDREN: PROBLEMS AND PROSPECTS. Russian Pediatric Journal, 2019, 20, 99-107.	0.0	4
346	Dupilumab Efficacy and Safety in Adolescents with Moderate-to-Severe Atopic Dermatitis: A Case Series. Acta Dermato-Venereologica, 2020, 100, 1-2.	0.6	12
347	A Therapeutic Renaissance - Emerging Treatments for Atopic Dermatitis. Acta Dermato-Venereologica, 2020, 100, adv00165.	0.6	7
348	An update on biological therapies for pediatric allergic diseases. Minerva Pediatrica, 2020, 72, 364-371.	2.6	8
349	Dupilumab for atopic dermatitis: evidence to date. Giornale Italiano Di Dermatologia E Venereologia, 2019, 154, 696-713.	0.8	14
350	Effect of a Product Containing Xyloglucan and Pea Protein on a Murine Model of Atopic Dermatitis. International Journal of Molecular Sciences, 2020, 21, 3596.	1.8	14
351	Tumor lysis syndrome in childhood malignancies. Drugs in Context, 2020, 9, 1-14.	1.0	21
352	Conjunctivitis in patients with atopic dermatitis treated with dupilumab. Drugs in Context, 2020, 9, 1-8.	1.0	20
353	Dupilumab for Atopic Dermatitis: The Silver Bullet We Have Been Searching for?. Cureus, 2020, 12, e7565.	0.2	11
354	Efficacy of biologics and oral small molecules for atopic dermatitis: a systematic review and meta-analysis. Journal of Dermatological Treatment, 2022, 33, 2534-2544.	1.1	5
355	Anti-Interleukin Biologics for the treatment of the Atopic March Diseases. , 0, , 1-27.		2
356	Drug Repurposing for Atopic Dermatitis by Integration of Gene Networking and Genomic Information. Frontiers in Immunology, 2021, 12, 724277.	2.2	18
357	Effects of systemic therapies on pruritus in adults with atopic dermatitis: a systematic review and meta-analysis. Clinical and Experimental Dermatology, 2022, 47, 658-666.	0.6	9
358	Mesenchymal stem/stromal cell therapy in atopic dermatitis and chronic urticaria: immunological and clinical viewpoints. Stem Cell Research and Therapy, 2021, 12, 539.	2.4	5
359	Emerging Role of Tacrolimus in the Treatment of Atopic Dermatitis : Recent Advances. Nishinohon Journal of Dermatology, 2016, 78, 468-473.	0.0	0
361	Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 0, , .	0.9	2
362	Future Trends on Treatment of Atopic Dermatitis. Nishinohon Journal of Dermatology, 2017, 79, 447-454.	0.0	0

#	ARTICLE	IF	CITATIONS
364	Monoclonal Antibodies for Immune System-Mediated Diseases. , 2019, , 369-406.		0
365	Inflammation of the Skin and Its Therapeutic Targets. , 2020, , 141-174.		1
366	Efficacy, Safety, and Immunomodulatory Effect of the Intramuscular Administration of Autologous Total Immunoglobulin G for Atopic Dermatitis: A Randomized Clinical Trial. Allergy, Asthma and Immunology Research, 2020, 12, 949.	1.1	13
367	Biological drugs in the treatment of atopic dermatitis – current recommendations of the Polish Dermatological Society, the Polish Society of Allergology, the Polish Pediatric Society and the Polish Society of Family Medicine. Postepy Dermatologii I Alergologii, 2020, 37, 617-624.	0.4	1
368	New Era in Atopic Dermatitis Treatment: Results of Long-Term Dupilumab Administration. Voprosy Sovremennoi Pediatrii - Current Pediatrics, 2021, 20, 390-395.	0.1	1
369	Immunological Targets of Biologic Drugs in Allergic Skin Diseases in Children. Biomedicines, 2021, 9, 1615.	1.4	6
371	Biologic Treatment Options for Pediatric Psoriasis and Atopic Dermatitis-A Review. Journal of Clinical and Aesthetic Dermatology, 2020, 13, S33-S38.	0.1	2
372	Efficacy of Dupilumab in Atopic Dermatitis: The Patient’s Perspective. Dermatology and Therapy, 2021, 11, 2123-2131.	1.4	0
373	Peripheral Mechanisms of Itch. Journal of Investigative Dermatology, 2022, 142, 31-41.	0.3	15
374	Dupilumab with Topical Corticosteroids Provides Rapid and Sustained Improvement in Adults with Moderate-to-Severe Atopic Dermatitis Across Anatomic Regions Over 52 Weeks. Dermatology and Therapy, 2022, 12, 223-231.	1.4	7
375	Unique molecule filaggrin in epidermal structure and its role in the xerosis development and atopic dermatitis pathogenesis. Klinicheskaya Dermatologiya I Venerologiya, 2021, 20, 102.	0.0	2
376	Biologic Therapies for Severe Asthma. New England Journal of Medicine, 2022, 386, 157-171.	13.9	268
377	Biological medication in atopic dermatitis. Expert Opinion on Biological Therapy, 2022, , 1-7.	1.4	5
378	Dupilumab Treatment Reduces Hospitalizations in Adults With Moderate-to-Severe Atopic Dermatitis. Journal of Allergy and Clinical Immunology: in Practice, 2022, 10, 1279-1285.e1.	2.0	7
379	Treatment Outcomes Associated With Dupilumab Use in Patients With Atopic Dermatitis. JAMA Dermatology, 2022, 158, 142.	2.0	8
380	Dupilumab-associated ocular manifestations: A review of clinical presentations and management. Survey of Ophthalmology, 2022, 67, 1419-1442.	1.7	12
381	Preclinical and clinical experience with dupilumab on the correlates of live attenuated vaccines. , 2022, 1, 9-15.		7
382	Incidence of Bacterial and Nonbacterial Conjunctivitis in Patients With Atopic Dermatitis Treated With Dupilumab: A US Multidatabase Cohort Study. Dermatitis, 2022, 33, S73-S82.	0.8	3

#	ARTICLE	IF	CITATIONS
383	Dupilumab for the treatment of atopic dermatitis: real-world data from the Czech Republic BIOREP registry. <i>Journal of Dermatological Treatment</i> , 2022, 33, 2578-2586.	1.1	8
384	Ocular Adverse Effects in Atopic Dermatitis Patients Treated With Dupilumab: A Bibliometric Analysis. <i>Frontiers in Medicine</i> , 2022, 9, 802036.	1.2	4
385	Clinical Characteristics and Treatment for Dupilumab-Related Ocular Complications in Atopic Dermatitis Patients. <i>Clinical Ophthalmology</i> , 2022, Volume 16, 947-958.	0.9	6
386	Immune mechanisms of atopic dermatitis and new approaches to targeted biological therapy. <i>Meditinskiy Sovet</i> , 2022, , 130-136.	0.1	0
387	Respiratory Infections and Anti-Infective Medication Use From Phase 3 Dupilumab Respiratory Studies. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 732-741.	2.0	16
388	Pharmacokinetics of Subcutaneous Dupilumab Injection With an Autoinjector Device or Prefilled Syringe. <i>Clinical Pharmacology in Drug Development</i> , 2022, , .	0.8	3
389	Prescription Market Share and Treatment Patterns in Atopic Dermatitis: A Retrospective Observational Study Using US Insurance Claims. <i>Advances in Therapy</i> , 2022, 39, 2052-2064.	1.3	3
390	Current approaches to the treatment of atopic dermatitis: a review of the literature. <i>Russian Journal of Skin and Venereal Diseases</i> , 2021, 24, 375-385.	0.0	0
391	Deacetylasperulosidic Acid Ameliorates Pruritus, Immune Imbalance, and Skin Barrier Dysfunction in 2,4-Dinitrochlorobenzene-Induced Atopic Dermatitis NC/Nga Mice. <i>International Journal of Molecular Sciences</i> , 2022, 23, 226.	1.8	8
393	Dupilumab Provides Acceptable Safety and Sustained Efficacy for up to 4 Years in an Open-Label Study of Adults with Moderate-to-Severe Atopic Dermatitis. <i>American Journal of Clinical Dermatology</i> , 2022, 23, 393-408.	3.3	36
394	Indirect Treatment Comparison of Baricitinib versus Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis. <i>Dermatology and Therapy</i> , 2022, 12, 1481-1491.	1.4	7
395	Real-World Effectiveness of Dupilumab in Atopic Dermatitis Patients: Analysis of an Electronic Medical Records Dataset. <i>Dermatology and Therapy</i> , 2022, 12, 1337-1350.	1.4	3
396	Long-Term Efficacy and Safety of Dupilumab in Adolescents with Moderate-to-Severe Atopic Dermatitis: Results Through Week 52 from a Phase III Open-Label Extension Trial (LIBERTY AD PED-OLE). <i>American Journal of Clinical Dermatology</i> , 2022, 23, 365-383.	3.3	30
397	Atopic dermatitis: pathomechanisms and lessons learned from novel systemic therapeutic options. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2022, 36, 1432-1449.	1.3	28
398	Practical issues in the use of emollients containing filaggrin modulators in the management of patients with atopic dermatitis and xerosis: Resolution of the Expert board. <i>Russian Journal of Allergy</i> , 2022, 19, 245-258.	0.1	1
399	Effect of Dupilumab on Blood Eosinophil Counts in Patients With Asthma, Chronic Rhinosinusitis With Nasal Polyps, Atopic Dermatitis, or Eosinophilic Esophagitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2022, 10, 2695-2709.	2.0	72
400	IL-4/IL-13 axis as therapeutic targets in allergic rhinitis and asthma. <i>PeerJ</i> , 0, 10, e13444.	0.9	25
401	IgG Autoantibodies Against IgE from Atopic Dermatitis Can Induce the Release of Cytokines and Proinflammatory Mediators from Basophils and Mast Cells. <i>Frontiers in Immunology</i> , 2022, 13, .	2.2	12

#	ARTICLE	IF	CITATIONS
402	Efficacy and Safety of Multiple Dupilumab Dose Regimens in Patients with Moderate-To-Severe Atopic Dermatitis: A Systematic Review and Network Meta-Analysis of Randomized Controlled Trials. <i>Dermatology</i> , 2022, 238, 1060-1072.	0.9	0
403	Dupilumab-induced hypereosinophilia: review of the literature and algorithm proposal for clinical management. <i>Expert Review of Respiratory Medicine</i> , 2022, 16, 713-721.	1.0	31
404	Efficacy and safety of dupilumab in the treatment of moderate-to-severe atopic dermatitis: a meta-analysis of randomized controlled trials. <i>Postepy Dermatologii I Alergologii</i> , 2022, 39, 601-610.	0.4	3
405	Clinical phenotypes of adult atopic dermatitis and related therapies. <i>Current Opinion in Allergy and Clinical Immunology</i> , 2022, 22, 242-249.	1.1	32
406	Patient-centered dupilumab dosing regimen leads to successful dose reduction in persistently controlled atopic dermatitis. <i>Allergy: European Journal of Allergy and Clinical Immunology</i> , 2022, 77, 3398-3407.	2.7	19
407	Allergic Asthma in the Era of Personalized Medicine. <i>Journal of Personalized Medicine</i> , 2022, 12, 1162.	1.1	13
408	Comparative Efficacy and Safety of Monoclonal Antibodies and Janus Kinase Inhibitors in Moderate-to-severe Atopic Dermatitis: A Systematic Review and Meta-analysis. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00764.	0.6	10
409	Chronic Pruritus in Atopic Patients Treated with Dupilumab: Real Life Response and Related Parameters in 354 Patients. <i>Pharmaceuticals</i> , 2022, 15, 883.	1.7	15
410	Adverse effects of dupilumab in chronic rhinosinusitis with nasal polyps. Case report and narrative review. <i>Acta Otorhinolaryngologica Italica</i> , 2022, 42, 199-204.	0.7	4
411	Racial and ethnic diversity of US participants in clinical trials for acne, atopic dermatitis, and psoriasis: a comprehensive review. <i>Journal of Dermatological Treatment</i> , 2022, 33, 3086-3097.	1.1	9
412	Pharmacokinetics, pharmacodynamics, and exposure-efficacy of dupilumab in adults with atopic dermatitis. <i>Clinical and Translational Science</i> , 2022, 15, 2342-2354.	1.5	3
413	English Version of Clinical Practice Guidelines for the Management of Atopic Dermatitis 2021. <i>Journal of Dermatology</i> , 2022, 49, .	0.6	9
414	Effectiveness and Safety of Upadacitinib in the Treatment of Moderate-Severe Atopic Dermatitis: A Multicentric, Prospective, Real-World, Cohort Study. <i>Drugs in R and D</i> , 2022, 22, 245-252.	1.1	26
415	Adjusted dose regimens in dupilumab treatment for atopic dermatitis: Daily practice experiences. , 2022, 1, 355-363.		0
416	Impact of a Decade of Research Into Atopic Dermatitis. <i>Journal of Allergy and Clinical Immunology: in Practice</i> , 2023, 11, 63-71.	2.0	18
417	Experience with dupilumab in patients with atopic dermatitis. <i>Allergologia I Immunologia V Pediatrii</i> , 2022, , 14-23.	0.1	0
418	Dupilumab: Advances in the off-label usage of IL4/IL13 antagonist in dermatoses. <i>Dermatologic Therapy</i> , 2022, 35, .	0.8	6
419	Efficacy of Dupilumab on Different Phenotypes of Adult with Moderate-to-Severe Atopic Dermatitis in Taiwan: A Real-World Study. <i>Journal of Clinical Medicine</i> , 2022, 11, 6209.	1.0	2

#	ARTICLE	IF	CITATIONS
420	Callicarpa dichotoma Leaf Extract Alleviates Atopic Dermatitis through the Suppression of T Cells and Keratinocytes Activation. <i>Pharmaceuticals</i> , 2022, 15, 1280.	1.7	0
421	Treatment With Dupilumab in Patients With Atopic Dermatitis: Systematic Review and Meta-Analysis. <i>Journal of Cutaneous Medicine and Surgery</i> , 2022, 26, 613-621.	0.6	9
422	Association of Serum Dupilumab Levels at 16 Weeks With Treatment Response and Adverse Effects in Patients With Atopic Dermatitis. <i>JAMA Dermatology</i> , 2022, 158, 1409.	2.0	3
423	D-Mannose ameliorates DNCB-induced atopic dermatitis in mice and TNF- α -induced inflammation in human keratinocytes via mTOR/NF- κ B pathway. <i>International Immunopharmacology</i> , 2022, 113, 109378.	1.7	3
424	Atopic Dermatitis: Clinical Aspects and Unmet Needs. <i>Biomedicines</i> , 2022, 10, 2927.	1.4	3
425	Daily Practice Experience of Baricitinib Treatment for Patients with Difficult-to-Treat Atopic Dermatitis: Results from the BioDay Registry. <i>Acta Dermato-Venereologica</i> , 0, 102, adv00820.	0.6	9
426	Efficacy of topical and systemic treatments for atopic dermatitis on pruritus: A systematic literature review and meta-analysis. <i>Frontiers in Medicine</i> , 0, 9, .	1.2	3
427	An anti-OX40 antibody to treat moderate-to-severe atopic dermatitis: a multicentre, double-blind, placebo-controlled phase 2b study. <i>Lancet, The</i> , 2023, 401, 204-214.	6.3	38
429	Insights into atopic dermatitis pathogenesis lead to newly approved systemic therapies. <i>British Journal of Dermatology</i> , 2023, 188, 698-708.	1.4	8
430	Efficacy and safety of etrasimod, a sphingosine 1-phosphate receptor modulator, in adults with moderate-to-severe atopic dermatitis (<scp>ADVISE</scp>). <i>Journal of the European Academy of Dermatology and Venereology</i> , 2023, 37, 1366-1374.	1.3	6
431	Oral Janus kinase inhibitors for atopic dermatitis. <i>Annals of Allergy, Asthma and Immunology</i> , 2023, 130, 577-592.	0.5	13
432	Therapeutic Relief for Erythrodermic Atopic Dermatitis. <i>JAMA Dermatology</i> , 2023, 159, 247.	2.0	0
433	Efficacy and Safety of Dupilumab in Patients With Erythrodermic Atopic Dermatitis. <i>JAMA Dermatology</i> , 2023, 159, 255.	2.0	6
434	Blockage of the IL-31 Pathway as a Potential Target Therapy for Atopic Dermatitis. <i>Pharmaceutics</i> , 2023, 15, 577.	2.0	7
435	A Review on the Safety of Using JAK Inhibitors in Dermatology: Clinical and Laboratory Monitoring. <i>Dermatology and Therapy</i> , 2023, 13, 729-749.	1.4	35
436	Efficacy of dupilumab in moderate and severe atopic dermatitis. , 2023, 2, 247-260.		1
437	Dupilumab long-term efficacy in patients with non-“OCS”-dependent asthma with and without evidence of allergic asthma. <i>Journal of Asthma</i> , 0, , 1-10.	0.9	0
438	Association between Dupilumab and Conjunctivitis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. <i>Pharmaceutics</i> , 2023, 15, 1031.	2.0	1

#	ARTICLE	IF	CITATIONS
439	Crisaborole reverses dysregulation of the mild to moderate atopic dermatitis proteome toward nonlesional and normal skin. <i>Journal of the American Academy of Dermatology</i> , 2023, 89, 283-292.	0.6	1
440	Systematic review and estimated cost-efficacy of biologics compared with narrowband ultraviolet B light for the treatment of moderate to severe psoriasis and atopic dermatitis. <i>International Journal of Dermatology</i> , 2023, 62, 986-999.	0.5	3
445	Recent developments in the use of monoclonal antibodies targeting the type 2 cytokines for severe asthma treatment. <i>Advances in Pharmacology</i> , 2023, , 31-54.	1.2	0
459	A Mini Review of the Impact of Baseline Disease Severity on Clinical Outcomes: Should We Compare Atopic Dermatitis Clinical Trials?. <i>Dermatology and Therapy</i> , 2023, 13, 3019-3029.	1.4	2
471	Treatment of AD with Dupilumab. <i>Clinical Cases in Dermatology</i> , 2024, , 85-96.	0.0	0